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Abstract
We introduce a Unified Disentanglement Network (UFDN) trained on The Can-
cer Genome Atlas (TCGA). We demonstrate that the UFDN learns a biologically
relevant latent space of gene expression data by applying our network to two clas-
sification tasks of cancer status and cancer type. Our UFDN specific algorithms
perform comparably to random forest methods. The UFDN allows for continu-
ous, partial interpolation between distinct cancer types. Furthermore, we perform
an analysis of differentially expressed genes between skin cutaneous melanoma
(SKCM) samples and the same samples interpolated into glioblastoma (GBM).
We demonstrate that our interpolations learn relevant metagenes that recapitulate
known glioblastoma mechanisms and suggest possible starting points for investiga-
tions into the metastasis of SKCM into GBM.
1 Introduction
Deep learning is being applied to many difficult problems in genomics and medicine. Alipanahi
et al. used deep learning to learn site specific binding patterns of DNA and RNA-binding proteins
[1]. Zhou et al. were able to predict non-coding variants using deep learning [2]. Google has even
produced an improved variant caller known as DeepVariant [3].
More specifically, deep learning has been applied to understanding cancer prognosis. Chaudhary et al.
were able to robustly predict survival in liver cancer [4]. Cruz-Roa et al. leveraged deep learning to
quantify the extent of breast cancer tumors in imaging data [5]. Other groups have trained networks
to identify metastatic breast cancer and lymph node metastasis [6, 7].
Nevertheless, there is little work in machine learning being done on what changes are occurring at a
gene expression level in cancer samples. Understanding the genomic basis of cancer will yield better
treatments and prognosis for patients [8]. There are significant questions remaining in oncology
about the relationships between different cancer types. For instance, while there is an association
between melanoma, a type of skin cancer, and glioblastoma, a type of brain cancer, little is known
about the molecular underpinnings of this relationship [9, 10].
Recently, deep generative models such as variational auto encoders (VAEs) and generative adversarial
networks (GANs) have made large advances in image, audio, and text generation [11, 12, 13]. VAEs
and GANs learn generative distributions on lower-dimensional encodings of input data [14]. VAEs
have found genomic applications. Rampasek et al. applied VAEs to learn drug responses based on
gene expression data [15]. Way et al. trained a VAE called Tybalt to encode The Cancer Genome
Atlas (TCGA) [14]. Huang et al. have developed a theory of cancer development as a progression
along a low dimensional space, justifying exploration of cancer metastasis using machine learning
algorithms that learn low dimensional representations [16].
A new VAE-GAN hybrid architecture known as the Unified Feature Disentanglement Network
(UFDN) learns fundamental features that distinguish input domains [17]. For multiple input data
types, such as photographs, sketches, and watercolor paintings, the UFDN learns an VAE encoding
of the data domains and trains a discriminator in the latent space to discriminate between domain
types. Then, the UFDN can subsequently encode data from one domain and decode the data into a
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different domain[17]. An additional GAN distinguishes between real/fake images in the pixel space
to promote high quality decodings[17].
In this work, we apply this new UFDN architecture to TCGA RNA-Seq data and learn a latent space
embedding that allows us to convert between different cancer types given gene expression data. Given
gene expression levels in a cancer sample of domain A, we can predict gene expression levels as if
that cancer sample were of domain B. This represents a generative, personalized model of metastasis.
We can sample points in our latent space encoding and decode them into any new cancer domain.
Additionally, we can partially interpolate between cancer domains. UFDN decoding is not strictly
binary—input data can be decoded into a mix of output domains. We investigate partial interpolations
of one cancer type into another, mimicking the progressive nature of metastasis.
We analyze the performance of our TCGA-trained UFDN on two tasks: predicting whether a sample
is from cancerous or normal tissue and predicting which cancer sub-type a sample consists of.
Additionally, we investigate partial interpolations from skin cutaneous melanoma (SKCM) TCGA
samples to glioblastoma (GBM) by looking at differential expression of genes. We compute metagenes
that summarize gene expression changes using integrative non-negative matrix factorization. Finally,
we analyze Gene Ontology (GO) term enrichment in highly activated metagenes for each interpolated
dataset.
Figure 1: The overall workflow of our project. We aimed to identify the crucial changes in gene
expression as cancer metastasizes from the original location to a new location. We encoded RNA-
Seq samples from skin cutaneous melanoma, decoded them into glioblastoma, and then applied 3
bioinformatics tools to analyze which sets of genes were changing between cancer types.
2 Methods
2.1 Data Preprocessing
The data consisted of 10,433 samples of RNA-Seq gene expression levels across 33 cancer types for
20,501 genes from TCGA obtained via the R Package curatedTCGA [18, 19]. For the purpose of
this work, we only considered the RSEM (RNA-Seq by Expectation Maximization [20]) normalized
expression levels. We divided 70%, 20%, and 10% to train, test, and holdout datasets, respectively.
Tybalt demonstrated that preprocessing gene expression levels by scaling gene-wise expression levels
(across all samples) to between 0 and 1 yields a trainable latent space [14]. We adapted this procedure
by first clipping expression levels to fall within 3 standard deviations from the mean of gene-wise
expression levels followed by the same min-max normalization of Tybalt [14].
2.2 UFDN
2.2.1 Theory
Liu et al. develop a UFDN as a combination of an encoder E, a generator G, and two discriminators:
Dv in the latent space and Dx in the pixel space [17]. In our application, pixel space is replaced
by “gene expression space.” E takes input data and encodes it in a latent space. In our UFDN, we
encode gene expression using fully connected networks. Dv learns to discriminate between domains,
or cancer types. Then generator G uses a latent space encoding and a domain vector dv to produce
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gene expression data in domain v [17]. Our UFDN uses dv ∈ R33 since there are 33 cancer types in
TCGA.
We define a partial interpolation with parameter p ∈ [0, 1] of an input of domain c to domain cˆ to be
the decoding of the input into into a composition of domains c and cˆ, with weight p given to domain
cˆ. That is, the domain vector of the partial interpolation has components dvcˆ = p, dvc = 1 − p,
and remaining components zero. For instance, a 0.25-GBM interpolation means an input has been
decoded with dvGBM = 0.25 and original domain entry is 0.75.
In the pixel space (or gene expression space), Dx learns to distinguish between samples that have
been decoded to their original domain c or a new domain cˆ [17]. The network is trained by iterative
stochastic gradient updates to E, Dv, and Dx. For a more detailed exposition of the architecture of
and gradient updates for training the UFDN, please see Section 3 of Liu et al. 2018 [17].
The encoder E and generator G are single layer networks, each with 500 hidden units, that learn a
100 dimensional latent space. The feature space discriminator Dv is a single layer network with 64
hidden units and the pixel space discriminator Dx is a two layer network with 500 and 100 hidden
units. All networks are fully connected with leaky relu activation functions. We use 50,000 iterations
of Adam updates with a learning rate of 10−4.
2.2.2 Classification Tasks
We attempted two classification tasks using the UFDN. The first was classifying a sample as tumor or
normal. This is referred to as the cancer status task. The second task was predicting cancer domain,
one of 33 sub-types in the TCGA.
In order to solve these tasks, we developed 3 algorithms using UFDN:
• UDFN-MSE: classify a sample’s type by encoding the sample and decoding it into all 33
domains, predicting the type of the domain with lowest reconstruction error as defined by
mean square error (MSE).
• Unsupervised UFDN: Inspired by the unsupervised domain adaptation experiments from
Liu et al.[17], this algorithm predicts cancer status by encoding a sample into the latent
space, then decoding it into the mesothelioma domain, regardless of input domain. We
trained a random forest classifier to predict cancer status on mesothelioma training data.
Use the prediction of this classifier to predict cancer status in the original input domain. The
motivation for this approach is that the classifier trained on mesothelioma data is strong but
the test data of interest is of a different cancer type.
• Semi-supervised UFDN: A hybrid of the two above algorithms used to predict cancer status
and type. First, predict cancer type using UDFN-MSE. Then, predict cancer status using a
random forest classifier trained on that specific type’s status data.
2.3 Interpolation Analysis
We encoded 95 samples of SKCM (skin cutaneous melanoma) from our test set partition of the TCGA
into our latent space using our trained UFDN. Then, we interpolated the samples into glioblastoma
(GBM) at four different fractions of interpolation: 25%, 50%, and 75%, and 100%. The 100%
interpolation represents a prediction of gene expression levels of the SKCM samples as GBM per
sample.
In order to analyze how gene expression changed between SKCM samples and these samples as
GBM, we performed a differential expression analysis using edgeR [21, 22]. This is an R package
that uses a negative binomial distribution model to analyze significant gene expression changes
between two groups [21, 22]. Although normally edgeR works with raw read counts, more recently
the package creator has stated that RSEM normalized reads are also suitable for use with edgeR [23].
We applied the inverse transformation of our min-max normalization to our four interpolated datasets
since our UFDN decodes gene expression levels to the range [0,1]. Then we used edgeR to find
differentially expressed genes between SKCM samples and 100% GBM interpolated samples. A
p-value threshold for differential expression was set at p = .05/20501 = 2.438 ∗ 10−6 to control for
false discovery.
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Analyzing every single gene the significantly changed between SKCM and GBM would be a chal-
lenge, so we used integrative Non-negative Matrix Factorization (IntNMF) to learn metagenes that
summarized gene expression changes [24]. IntNMF learns a reduced dimensionality representation
across multiple datasets [24]. IntNMF learns a shared basis matrix W ∈ Rp×k and where p is the
number of features (here, the differentially expressed genes) and k is the number of metagenes,
k << p. Each dataset Dj is described by a learned matrix Hj ∈ Rk×n where n is the number of
samples in the dataset [24]. Each row of Hj represents the linear combination of metagenes of W
that combine to reconstruct the original sample in Dj [24]. We chose k = 60 based on an analysis of
the reconstruction error
∑
j ||Dj −WHj ||F , where F is the Frobenius norm. We learned W and Hj
for each dataset using the R package IntNMF [24].
Every element g of column W (i) is non-negative and represents the contribution of gene g to the i-th
metagene [24]. Each element s of the n-th row of Hj represents the contribution of metagene s to
the n-th sample of the j-th dataset. We can analyze how these metagenes change over the different
interpolation datasets in order to understand how gene expression is changing [24].
Finally, to understand the broad composition of the metagenes discovered by IntNMF, we used
Gene Ontology (GO) enrichment analysis. GO terms are an ontology of three categories: biological
processes, molecular function, and cellular component. They link together information about the
functions and relationships of genes and proteins. topGO is an R package that analyzes if GO terms,
which have been mapped to genes, show up more often than expected in a set of genes and associated
scores for each gene [25].
We used a Kolmogorov-Smirnov like test known as Gene Score Enrichment Analysis that calculates
p-values of enrichment based on a score for each gene[25]. In our work, we did this test on each
metagene derived from IntNMF with the score for gene g as W (i)g [25]. By looking at the top scoring
GO terms for each metagene, we understand what sort of genes are changing as we interpolate
between cancer types [25].
2.4 Code
All our code is available at https://github.com/bkompa/UFDN-TCGA. We used Liu et al.’s
implementation of UFDN as a starting point but had to expand the architecture to work with an
arbitrary number of domains. We wrote all other code used for analysis with the various packages
mentioned above.
3 Results
3.1 UFDN Training and Performance
First, we validated that our UFDN learned a non-trivial latent space representation of TCGA RNA-Seq
data. We projected both the TCGA data and latent space encodings into UMAP space [26]. UMAP
learns a Riemann manifold representation of the data [26]. We used hyper-parameters spread=2.0
and min_dist=.01 to produce Figure 2. We observed distinct clusters by cancer types for both the
original data and encodings. We proceeded in our downstream analysis confident that our UFDN had
learned how to discern between cancer types based on these UMAP projections.
Next, we estimated the ability of our UFDN to take data from a source domain (original cancer
type) and interpolate these data into a target domain (new cancer type). We considered the fraction
of the k nearest neighbors, in the training data, of the interpolated samples that were in the target
domain as a measure of success. These decoding rates are shown in Figure 3. There were certain
cancers that the UFDN was able to more robustly interpolate into. These included glioblastoma, acute
myloid leukemia, mesothelioma, and prostate adenocarcinoma, among others. Difficult cancers to
interpolate into were sarcomas, which are a heterogeneous subcategory of soft tissue cancers and
cervical squamous cell carcinoma.
Finally, we analyzed our UFDN’s performance on two classification tasks: cancer status prediction
and cancer type prediction. Table 1 reports the performances of our three UFDN classification
algorithms as compared to a random forest baseline. The random forests had a maximum depth of
15 and were composed of 100 trees. The semi-supervised UFDN algorithm was able to match the
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Figure 2: UMAP projections of the RNA-Seq TCGA data (Figure 2A) and UFDN latent space
encodings of said data (Figure 2B). The full 20,501 dimensional representation of gene expression
levels have more cancer specific clusters. The 100 dimensional latent space encodings of these
samples still clustered in the UMAP space, though to a lesser extent.
Figure 3: The fraction of k nearest neighbors that were in the target domain (the rows of the
figures) after decoding from a source domain (the columns of the figures). Some domains were
noticeably more difficult to interpolate into. Glioblastoma had strong interpolation results across
k ∈ [1, 5, 10, 20].
Table 1: Results on two classification tasks compared to a random forest baseline.
Algorithm Cancer Status Acc (Train/Test) Cancer Type Acc (Train/Test)
Random Forests 99.60%/98.41% 99.65%/95.20%
UFDN-MSE — 96.51%/94.10%
Unsupervised UDFN 95.60%/86.14% —
Semi-supervised UDFN 99.60%/98.41% 96.51%/94.10%
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performance of random forests on the cancer status task and was comparable on the cancer type task.
Other UFDN algorithms were less successful compared to the baseline.
3.2 Gene Expression Changes
After interpolating 95 samples of SKCM from the test set into GBM, we analyzed which genes had
significant changes in expression between the SKCM and 1.0-GBM samples. Using edgeR, we looked
for genes that had differential expression that exceeded a significance threshold of p = 2.43 ∗ 10−6.
There were 10,557 genes that exceeded this threshold. Figure 4 shows the plot of average log
fold change versus average log counts per million and highlights the differentially expressed genes
between the two groups.
Figure 4: Differential expressed genes at a Bonferroni corrected p-value of 2.43 ∗ 10−6. These genes
are shown in red, while non DE genes are in black. 10,557 genes were differential expressed between
skin cancer samples and 1.0-glioblastoma interpolated skin cancer samples.
For the 10,557 differential expressed genes, we learned a shared basis W using IntNMF. By varying
the rank of that basis, we were able to decrease the reconstruction error across datasets SKCM,
0.25-GBM, 0.5-GBM, 0.75-GBM, and 1.0-GBM. Figure 5 reports how k affected the reconstruction
error. We chose k = 60 for subsequent analysis based on the inflection point of this reconstruction
curve. Hutchins et al. suggest that this is an optimal way to select k for NMF [27]. k = 60 was also
chosen for computational considerations. Optimizing Hj and W for k = 60 took nearly 7 hours and
increasing k much more would significantly increase this considerable time requirement.
Figure 5: Reconstruction error based on the Frobenius norm from IntNMF versus k, the rank of W
and Hj in IntNMF, on the x-axis as the number of metagenes. For subsequent analysis, k was chosen
to be 60 as error is nearly at an inflection point and plateauing.
Finally, we visualized the rows of Hj for each dataset in {SKCM, 0.25-GBM, 0.50-GBM, 0.75-
GBM, 1.00-GBM}. The columns of each heatmap in Figure 6 represent the relative activation of
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the respective metagene. As interpolation towards GBM increases, distinct metagenes increase their
responsibility for reconstructing Hj . In SKCM, metagene 36 has the most representation in the data.
For 0.25-GBM, 0.50-GBM, and 0.75-GBM, it was metagenes 15, 32, and 1, respectively.
In the 1.00-GBM heatmap (Figure 6 E), we saw the increased activation of metagene 23. When we
took 33 samples of TCGA GBM data from the test set and learned the matrix HGBM that minimized
reconstruction error ||DGBM −WHGBM ||F for the same, fixed, W learned previously by IntNMF,
we observed the same metagene 23 dominating (Figure 6 F).
Figure 6: Heatmap visualization of the Hj matrices for each interpolation of the SKCM test data set.
No row or column reordering was done to keep consistent metagene order across datasets. A full
interpolation of SKCM data into GBM data results in a consistent activation of metagene 23 (Figure
6E). This is replicated in HGBM (Figure 6F), which was optimized against the fixed W basis learned
for the other 5 datasets.
We proceeded to analyze the dominant metagene for every dataset Hj for GO term enrichment. In
the interest of space, we only report the top 15 most enriched GO terms for metagene 23 based on
p-value. Table 2 reports the GO term as well as p-value for each term.
4 Discussion
Our UFDN was able to learn a biologically relevant latent space encoding of TCGA data. Classi-
fication task results in Table 1 indicate that our UFDN was able to compete with random forests
that were trained on all 20,501 gene expression features. This indicates our algorithm was able to
learn an efficient, useful embedding of gene expression data. Figure 2 demonstrates that we learned
an encoding space that clustered cancers of the same domain. This likely facilitates successful
interpolation and classification between cancer domains. Additionally, our UFDN could robustly
interpolate into many cancer domains. Although Figure 3 demonstrates that not every cancer domain
was easy for the UFDN to decode into, one thing to note is that almost every column (target domain)
had at least one element with high decoding fraction. It’s possible to consider multiple interpolations
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Table 2: The top 15 Gene Ontology Terms enriched in metagene 23
GO ID Term p-value
GO:0003676 Nucleic acid binding 5.20E-19
GO:0003735 Structural constituent of ribosome 2.70E-15
GO:0003723 RNA binding 3.90E-14
GO:0003677 DNA binding 1.60E-12
GO:0005198 Structural molecule activity 3.80E-12
GO:0000981 DNA-binding transcription factor activit... 4.70E-12
GO:0003700 DNA-binding transcription factor activit... 3.50E-11
GO:0140110 Transcription regulator activity 2.80E-09
GO:0008376 Acetylgalactosaminyltransferase activity 4.10E-08
GO:0043492 ATPase activity, coupled to movement of ... 1.00E-07
GO:0060089 Molecular transducer activity 1.30E-07
GO:0004126 Cytidine deaminase activity 2.10E-07
GO:0019239 Deaminase activity 4.50E-07
GO:0048020 CCR chemokine receptor binding 7.30E-07
GO:0008009 Chemokine activity 8.10E-07
and potentially from converting from domain A to B to C would have a higher success rate than going
from A to C.
We learned 10,557 differentially expressed genes between SKCM and 1.0-GBM interpolated samples
as demonstrated in Figure 4. This reduction in dimensionality allowed us to make IntNMF computa-
tionally tractable. The lower number of genes considered in IntNMF, the faster the learning of the
shared basis W and dataset specific Hj . Analysis of the reconstruction error from IntNMF informed
our choice of 60 metagenes (see Figure 5). In Figure 6, we investigated how linear combinations of
these distinct metagenes reconstructed samples from many partially interpolated datasets. We ob-
served unique metagenes increasing activation for each partial interpolation. This is an approximation
of how gene expression profiles change during metastasis.
When we learned HGBM , the representation of TCGA GBM samples with respect to the basis W ,
something remarkable happened. Note that W was not informed by the TCGA dataset GBM at all.
W was simply the shared basis trained by IntNMF on interpolation datasets SKCM (equivalently,
0.00-GBM), 0.25-GBM, 0.5-GBM, 0.75-GBM, and 1.0-GBM. Yet when H1.0−GBM and HGBM
were compared side by side in Figure 6 E&F, their metagene activation profiles were dominated by
the same metagene 23. Therefore, our interpolation from SKCM to GBM successfully recapitulated
observed gene expression activity.
Furthermore, when we explored several of the GO terms identified by a GO term enrichment analysis,
metagene 23 was enriched for terms related to glioblastoma. GO:0008376 represents a glycoprotein
with a known association to glioblastoma [28, 29]. GO:0004126 refers to cytidine deaminase activity.
Cytidine deaminase gene therapy has been identified as a potential treatment for glioblastoma[30, 31].
GO:0048020 and GO:0008009 are associated with chemokines, which are implicated in glioblastoma
development [32, 33]. Our metagenes learned glioblastoma-specific genes and our UFDN interpolated
skin cancer samples to glioblastoma. Further analysis of the metagenes activated during interpolations
0.25-GBM, 0.50-GBM, and 0.75-GBM could provide starting points for the investigation of the
metastasis pathway from SKCM to GBM. This could help explain the association between melanoma
and glioblastoma that is not currently understood [9, 10].
5 Conclusion
Our UFDN learned a biologically relevant latent space that facilitated meaningful interpolations
between cancer domains. Our latent space can be used to generate more examples of transitions be-
tween cancers types. Our interpolations from SKCM to GBM have feasible biological interpretations
and suggest possible gene expression changes during the mysterious transition from melanoma to
glioblastoma.
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